Lv21
110 积分 2022-10-08 加入
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
3小时前
待确认
Current management of uncommon EGFR mutations in non-small cell lung cancer
4个月前
已完结
自身免疫性疾病与恶性肿瘤共病机制的研究进展
4个月前
已完结
Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis
11个月前
已完结
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3)
1年前
已关闭
Benefits and Relevant Risk Factor Assessment of Neoadjuvant Chemotherapy in Combination with Surgery in Limited-Stage Small-Cell Lung Cancer
1年前
已关闭
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
1年前
已完结
Multiple rechallenges with anti-PD-1 immunotherapy in patients with checkpoint inhibitor-related pneumonitis: A report of two cases
1年前
已完结
晚期非小细胞肺癌的免疫治疗再挑战
1年前
已完结
骨髓巨核细胞形态学分析
2年前
已采纳
血压的生物节律与高血压的时间治疗学
2年前
已采纳
皖公网安备34019202002308
